表紙
市場調査レポート

EpiCast Report:過敏性腸症候群(IBS)の疫学予測

EpiCast Report: Irritable Bowel Syndrome - Epidemiology Forecast to 2023

発行 GlobalData 商品コード 317757
出版日 ページ情報 英文 49 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.95円で換算しております。
Back to Top
EpiCast Report:過敏性腸症候群(IBS)の疫学予測 EpiCast Report: Irritable Bowel Syndrome - Epidemiology Forecast to 2023
出版日: 2014年10月27日 ページ情報: 英文 49 Pages
概要

過敏性腸症候群(IBS)は、腹部の不快感や痛み、膨満感、排便習慣の変化を特徴とする、慢性で再発する胃腸障害です。世界の主要7ヶ国(米国、フランス、ドイツ、イタリア、スペイン、英国、日本)で過敏性腸症候群(IBS)と診断された患者数は、2013年の4,077万人から、今後10年間で4,236万人まで、3.9%増加すると予測されています。

当レポートでは、世界の主要7ヶ国における過敏性腸症候群(IBS)について調査分析し、疾患の背景、危険因子と併存疾患、世界の動向、疫学予測などについて、体系的な情報を提供しています。

第1章 目次

第2章 イントロダクション

第3章 疫学

  • 疾患の背景
  • 危険因子と併存疾患
  • 世界の動向
    • 米国
    • EU5ヶ国
    • 日本
  • 予測手法
    • 利用した情報源
    • 利用しなかった情報源
    • 予測の前提条件と手法 - IBSの総患者数
    • 予測の前提条件と手法 - IBSのサブタイプ区分
  • IBSの疫学予測
    • IBSの総患者数
    • IBSの総患者数(年齢別)
    • IBSの総患者数(性別)
    • IBSの総患者数(年齢標準化)
    • IBSの総患者数(臨床サブタイプ別)
  • 議論
    • 疫学予測に関する考察
    • 分析の限界
    • 分析の強み

第4章 付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHCER068-14

Irritable Bowel Syndrome (IBS) is a chronic, relapsing gastrointestinal disorder that is characterized by abdominal discomfort or pain, bloating, and changes in bowel habit. Due to the lack of a demonstrable structural abnormality to explain these symptoms, IBS is classified as a functional gastrointestinal disorder.

IBS is one of the most common gastrointestinal disorders; moreover, it has a significant negative impact on a patient's quality of life and social functioning. That said, IBS is not known to be associated with the development of serious disease or with excess mortality. Several factors, including psychological disorders, stress, environmental factors, infection, and inflammation have been reported to play a role in the pathogenesis of IBS, however, their exact role remains to be clarified.

GlobalData epidemiologists forecast that the total prevalent cases of IBS in the 7MM will increase from 40,777,607 total prevalent cases in 2013 to 42,366,389 by 2023, at a decadal growth rate of 3.9%. Specifically, Spain will have the highest growth in the total prevalent cases of IBS in the 7MM between 2013 and 2023, while Japan and Germany will have a decline in the total prevalent cases of IBS in the 7MM between 2013 and 2023.

GlobalData's epidemiological analysis is supported by the use of epidemiological studies published in peer-reviewed journals and country-specific studies that provided the total prevalence of IBS using the Rome II diagnostic criteria. GlobalData epidemiologists used uniform methodology across the markets to forecast the total prevalent cases of IBS; GlobalData epidemiologists segmented IBS by sex, age, and subclassification of predominant bowel habits, which allows for a meaningful comparison of the disease populations between markets.

Scope

  • The Irritable Bowel Syndrome (IBS) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for IBS in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases of IBS segmented by sex, age (10-18 years, 19-34 years, 35-44 years, 45-54 years, 55-64 years, 65-74 years, 75-84 years, and =85 years), and subclassification of predominant bowel habits (diarrhea-predominant IBS [IBS-D], constipation-predominant IBS [IBS-C], mixed presentation IBS [IBS-M], and unsubtyped IBS [IBS-U] in these markets.
  • The IBS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global IBS market.
  • Quantify patient populations in the global IBS market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for IBS therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. US
    • 3.3.2. 5EU
    • 3.3.3. Japan
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods - Total Prevalent Cases of IBS
    • 3.4.4. Forecast Assumptions and Methods - IBS Subtype Segmentations
  • 3.5. Epidemiological Forecast for IBS (2013-2023)
    • 3.5.1. Total Prevalent Cases of IBS
    • 3.5.2. Age-Specific Total Prevalent Cases of IBS
    • 3.5.3. Sex-Specific Total Prevalent Cases of IBS
    • 3.5.4. Age-Standardized Total Prevalence of IBS
    • 3.5.5. Total Prevalent Cases of IBS by Clinical Subtype
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Acting Global Director of Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for IBS
  • Table 2: Comparison of the IBS Diagnostic Criteria Used in Epidemiological Studies
  • Table 3: Total Prevalence (%) of IBS in the 7MM, as Reported in Epidemiological Studies
  • Table 4: Total Prevalence (%) of IBS in the US, as Reported in Epidemiological Studies
  • Table 5: 7MM, Sources of Total Prevalence Data Used to Forecast the Total Prevalent Cases of IBS
  • Table 6: 7MM, Sources of IBS Subtype Data Used to Forecast the Total Prevalent Cases of IBS by Subtype
  • Table 7: 7MM, Total Prevalent Cases of IBS, Ages ≥10 Years, Both Sexes, N, Selected Years 2013-2023
  • Table 8: 7MM, Age-Specific Total Prevalent Cases of IBS, Both Sexes, N (Row %), 2013
  • Table 9: 7MM, Sex-Specific Prevalent Cases of IBS, Ages ≥10 Years, N (Row %), 2013
  • Table 10: 7MM Total Prevalent Cases of IBS, N (%), by Clinical Subtype, Both Sexes, Ages ≥10 Years, 2013

List of Figures

  • Figure 1: 7MM, Total Prevalent Cases of IBS Ages ≥10 Years, Both Sexes, N, 2013-2023
  • Figure 2: 7MM, Age-Specific Total Prevalent Cases of IBS, Both Sexes, N, 2013
  • Figure 3: 7MM, Sex-Specific Total Prevalent Cases of IBS, Ages ≥10 Years, N, 2013
  • Figure 4: 7MM, Age-Standardized Total Prevalence of IBS (%), Ages ≥10 Years, by Sex, 2013
  • Figure 5: 7MM Total Prevalent Cases of IBS (%), by Clinical Subtype, Both Sexes, Ages ≥10 Years, 2013
Back to Top